References
- Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev Immunol 2002;2:364–71.
- Taylor PC. Anti-TNFa therapy for rheumatoid arthritis: an update. Intern Med 2003;42:15–20.
- O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nature Rev Immunol 2002;2:37–45.
- Grom AA, Murray KJ, Luyrink L, Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Patterns of expression of tumour necrosis factor alpha, tumour necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Athritis Rheum 1996;39:1703–10.
- Muller K, Herner E, Stagg A, Bendtzen K, Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic onset juvenile chronic arthritis. Br J Rheumatol 1998;37:562–9.
- van Vollenhoven RF, Klareskog L. Clinical responses to tumour necrosis factor a antagonists do not show a bimodal distribution: data from the Stockholm Tumour Necrosis & Follow-up Registry. Arthritis and Rheumatism 2003;48: 1500–3.
- Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945–66.
- Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modelling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003;73:348–65.
- Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1) 13 and IL-1 receptor antagonist (IL-lra) to human serum. High-affinity binding of IL-lra to soluble IL-1 receptor type I. Cytokine 1993;5: 427–35.
- Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svensson M, et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 2004;22:118–24.
- Ridley D. Effective management of rheumatoid arthritis through dose titration of anti-TNF agents. Ann Rheum Dis 2002;61 Supp1:184 A .